In a report released yesterday, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical (GMED). The company’s shares closed yesterday at $46.55.
According to TipRanks.com, Turkaly is a 4-star analyst with an average return of 15.8% and a 61.9% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical Corporation, OrthoPediatrics Corp, and Haemonetics Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $55 average price target, representing a 18.2% upside. In a report issued on February 22, Oppenheimer also maintained a Hold rating on the stock with a $56 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $57.83 and a one-year low of $38.01. Currently, Globus Medical has an average volume of 731.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. is a medical device company, which engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments.
